Kite shoots for first CAR-T OK in Eu­rope, stay­ing one step be­hind No­var­tis in US race

Kite Phar­ma­ceu­ti­cals quite like­ly will come in a close sec­ond be­hind No­var­tis as they push their CAR-T drugs out in­to the cru­cial US mar­ket — but it still plans to be first mover in Eu­rope.

This morn­ing LA-based Kite says it was first in line at the EMA with an ap­pli­ca­tion for axi­cab­ta­gene ciloleu­cel — axi-cel — as a treat­ment for pa­tients with re­lapsed/re­frac­to­ry dif­fuse large B-cell lym­phoma (DL­B­CL), trans­formed fol­lic­u­lar lym­phoma (TFL), and pri­ma­ry me­di­asti­nal B-cell lym­phoma (PM­B­CL).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER